---
schema_version: "secwatch.filing_event.v1"
accession: "0001847367-25-000048"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:33:35.447420+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alumis Q3 net loss $110.8M; cash $377.7M; Phase 3 psoriasis data expected Q1 2026

## Summary
- Net loss of $110.8M for Q3 2025 vs. $93.1M in Q3 2024; R&D expenses rose to $97.8M from $87.8M.
- Cash, cash equivalents and marketable securities totaled $377.7M as of September 30, 2025.
- Topline Phase 3 ONWARD data for envudeucitinib in plaque psoriasis expected early Q1 2026; Phase 2b SLE data in Q3 2026.
- Collaboration revenue of $2.1M from Kaken Pharmaceutical in Q3 2025.
- Company expects existing cash to fund pipeline and operations into 2027.

## SEC filing metadata
- accession: 0001847367-25-000048
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/0001847367-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847367-25-000048
- JSON: https://secwatch.observer/filing/0001847367-25-000048.json
- Plain text: https://secwatch.observer/filing/0001847367-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.